Skip to content
Blog
5 min readBy Peptid AI EditorialEditorial policy

YK-11: A Tracking Guide for a Steroidal Myostatin-Claim Compound

A harm-reduction look at YK-11, a steroidal compound sold as a SARM with myostatin-inhibition claims, and why the human evidence is essentially absent.

At a glance

What it is
Steroidal compound marketed as a SARM
Route
Oral
Frequency
Daily, often split
Typical cycle
4-8 weeks
First effects
Uncertain

YK-11 is often sold as a selective androgen receptor modulator (SARM), but it is chemically a steroidal compound with a structure related to steroids rather than the non-steroidal SARMs. It is marketed with claims of myostatin inhibition, meaning it is promoted as removing a natural brake on muscle growth. The evidence for these claims in humans is essentially absent - most data comes from cell-culture studies.

This is an educational tracking guide, not a recommendation. YK-11 is an unapproved research chemical with minimal human data, and consumer products are frequently mislabeled.

What it is

  • A steroidal compound, not a true non-steroidal SARM
  • Promoted around myostatin-inhibition and follistatin claims from in-vitro work
  • Lacking meaningful human safety or efficacy data

Typical protocol shape

  • Taken orally, sometimes split due to a short half-life
  • Doses and durations commonly reported in research literature; this guide does not prescribe one
  • Often run in short blocks given how little is known

What to track daily

  • Bodyweight and training performance
  • Mood, libido, and energy
  • Any nausea or abdominal discomfort that could reflect liver stress

What to track weekly

  • Strength progression and bodyweight trend
  • Recovery and general well-being

Bloodwork worth doing

  • A liver panel (ALT, AST), given its steroidal nature
  • Total and free testosterone, LH, and FSH before, during, and after
  • A lipid panel

Realistic expectations

  • The myostatin-inhibition marketing far outruns the human evidence
  • Because it is steroidal, suppression and liver strain are plausible concerns
  • Outcomes are unpredictable and product quality is a major variable

Safety notes

The core honest point is that human data on YK-11 is minimal, so its real risk profile is poorly characterized. As a steroidal compound it likely suppresses natural testosterone and may stress the liver, and the myostatin claims rest on cell-culture work, not clinical trials. It is an unregulated research chemical, so mislabeling and contamination compound the uncertainty. Anyone using it should keep exposure short, monitor bloodwork, and plan for post-cycle recovery.

Peptid AI is an educational and self-tracking tool. Nothing in this post is medical advice. Doses mentioned reflect what is commonly reported in research literature — they are not recommendations. Always consult a qualified physician before starting, changing, or stopping any protocol.

Atlas entry

YK-11 — half-life, route and cautions

12 h · Oral

Build my plan Takes 2 minutes